Skip to main
SION

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 0%
Sell 11%
Strong Sell 0%

Bulls say

Sionna Therapeutics is poised for success as they have made significant progress in their research and development of new cystic fibrosis therapies, have a promising pipeline, and strong leadership with experience in the industry. However, potential risks from regulators and competition may pose a challenge for the company. With their predicted financial stability and data from Phase 2a studies expected in mid-2026, Sionna has the potential to bring significant benefits to those with CF and improve the treatment paradigm for this life-threatening disease.

Bears say

Sionna Therapeutics is a clinical-stage biotech with a portfolio of candidates aimed at treating cystic fibrosis (CF). Despite the large market and ongoing development initiatives, risks remain a concern due to the need for successful completion of ongoing clinical studies to validate the NBD1 mechanism and potential safety concerns. Additionally, the company may face financial risks in the form of continued losses and potential need for additional capital. However, if successful, the company could potentially capture a significant portion of the CF market, providing a major boost to its stock value.

SION has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 9 analysts, SION has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.